Kezar Life Sciences Inc reports results for the quarter ended in March - Earnings Summary

Kezar Life Sciences

11/05/2023 21:29

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 31 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 29 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 31 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kezar Life Sciences Inc shares had fallen by 16.9% this
quarter and lost 63.1% so far this year.
    * The company reported a quarterly loss of $22.2 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 08:29 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.29          -0.31          Missed
 Dec. 31 2022      -0.28          -0.25          Beat
 Sep. 30 2022      -0.27          -0.25          Beat
 Jun. 30 2022      -0.27          -0.25          Beat